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ABSTRACT 
This study reports on a preliminary structure-activity relationship exploration of 4-aryliden-2-
methyloxazol-5(4H)-one-based compounds as MAGL/FAAH inhibitors. Our results highlight that 
this scaffold may serve for the development of selective MAGL inhibitors. A 69-fold selectivity 
against MAGL over FAAH was achieved for compound 16b (MAGL and FAAH IC50 = 1.6 and 111 
µM, respectively). Furthermore, the best compound behaved as a reversible ligand and showed 
promising antiproliferative activity in cancer cells. 
 
Introduction 
The endocannabinoid system is involved in a large number of physiopathological processes, such 
as the regulation of cellular proliferation, pain sensation, appetite and cognition1. It is widespread in 
the mammalian tissues and it acts as a pro-homeostatic effector being activated following transient 
or chronic perturbation of homeostasis and locally regulating the levels and action of other chemical 
signals2. Among the various reported endogenous lipids with endocannabinoid-like activity, 2-
arachidonoylglycerol (2-AG) and arachidonoylethanolamide (AEA) are considered the two most 
important ligands of the CB1 and CB2 cannabinoid receptors. The signaling functions of AEA and 2-
AG are terminated by enzymatic hydrolysis, which is mainly mediated by the fatty acid amide 
hydrolase (FAAH) and monoacylglicerol lipase (MAGL), respectively3. The in vivo cannabinometic 
effects of the endocannabinoids are rather weak, due to the fact that they are rapidly inactivated by 
cellular reuptake followed by intracellular hydrolysis. However, an increase in the level of 
endocannabinoids, caused by a reduction of their metabolism promoted by FAAH or MAGL, could 
lead to several advantageous effects4. MAGL inhibition in the periphery produces CB1-dependent 
antinociceptive effects of noxious chemical, inflammatory, thermal, and neuropathic pain in mouse 
models5. Genetic and pharmacological blockades of MAGL also exhibit anti-inflammatory effects 
in the brain and neuroprotective effects for Parkinson's and Alzheimer's disease in mouse models6. 
Furthermore, other studies demonstrated that the inhibition of MAGL also exerts anti-anxiety 
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responses7 and can be useful for modulating opiate drug dependence8. Finally, MAGL is 
upregulated in aggressive cancer cells and primary tumors and its inhibition in aggressive breast, 
ovarian, and melanoma cancer cells impairs cell migration, invasiveness, and tumorigenicity9.  
Three different types of MAGL inhibitors have been reported in literature so far: 1) compounds 
that bind the enzyme covalently and irreversibly; 2) compounds that bind covalently and reversibly; 
3) compounds that bind non-covalently. Among the compounds that bind covalently, two different 
sub-types are reported, those that bind the nucleophilic serine 122 (S122) and those that target the 
cysteines of the enzyme3. This last class of MAGL inhibitors generally shows a high selectivity 
against FAAH; however, this selectivity over other enzymes containing cysteine residues in the 
binding site still needs to be verified. Regarding the MAGL inhibitors that bind the nucleophilic 
S122, a wide number of compounds have been reported in literature, but only few show high 
selectivity against FAAH. One of the most promising ligands was developed by Cravatt and co-
workers, and it consists of a carbamate derivative that behaves as an irreversible nanomolar 
inhibitor (JZL-184, Figure 1) and displays a high selectivity for MAGL versus FAAH enzymes10. 
In the last 5 years this compound has been used as a reference molecule for a wide number of in 
vitro and in vivo experimental studies. Very recently, Laitinen and co-workers, by combining the 
1,2,4-triazole leaving group together with the aromatic benzodioxolyl moiety, reported the 
development of compound JJKK-048 (Figure 1)11, which is probably the most active and selective 
irreversible MAGL inhibitor ever reported. CAY10499 (Figure 1) is a known irreversible inhibitor 
of both MAGL and FAAH enzymes12. Although CAY10499 is a carbamate-based inhibitor, just like 
many other compounds interacting with the enzymes of the endocannabinoid system, further studies 
revealed that the 5-methoxy-1,3,4-oxadiazol-2(3H)-one ring is the main responsible for MAGL 
inhibition. The structure-activity relationships of this compound and further MALDI- and SELDI-
TOF mass spectrometry analyses of analogous compounds12-13 strongly supported a covalent 
interaction of the 5-methoxy-1,3,4-oxadiazol-2(3H)-one moiety with the enzyme active site, which 
occurs by a nucleophilic attack of the hydroxyl group of the enzyme’s catalytic serine to the 
4 
 
carbonyl atom of the inhibitor’s oxadiazolone ring. The 1,3,4-oxadiazol-2(3H)-one heterocycle was 
also found in the scaffold of other MAGL and FAAH inhibitors; most of them, however, were 
completely unselective14 or characterized by a low selectivity for MAGL versus FAAH, such as 
compound 1 (Figure 1), with IC50 values of 0.35 M for MAGL and 6.3 M for FAAH
15-16. 
 
Figure 1. Structures of some of the most relevant MAGL inhibitors. 
 
On the basis of the ability of the 5-methoxy-1,3,4-oxadiazol-2(3H)-one moiety (I, Figure 2) to 
interact with the catalytic serine of MAGL, we decided to design and synthesize compounds 
possessing a similar 2-methyl-4-methyleneoxazol-5(4H)-one scaffold (II, Figure 2). Both structures 
are based on a cyclic carbamate or lactone moiety, which can be opened in the presence of a 
nucleophile; moreover, the geometry of the C-N bond, in which the nitrogen atom is present in 
position 3 of the 5-methoxy-1,3,4-oxadiazol-2(3H)-one cycle, could be mimicked by the 4-
arylidene portion of the 2-methyl-4-methyleneoxazol-5(4H)-one scaffold. Therefore, a series of 
three new exploratory small compounds 2, 3 and 4 (Schemes 1 and 2), were initially synthesized to 
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determine which kind of aromatic portion (Ar, Figure 2), such as phenyl (2) or heteroaromatic five-
membered cycle (3 and 4), was more suitable for obtaining good inhibition levels on MAGL. 
Further developments of this chemical class were carried out and nine new compounds (16a-c, 17a-
c and 18a-c, Scheme 3) were obtained by introducing unsubstituted or para-substituted (fluoro and 
methoxy) phenyl rings in the aromatic ring of compound 2. Finally, in order to verify whether the 2-
methyloxazol-5(4H)-one moiety was necessary for the activity on MAGL, we synthesized and 
tested a compound containing the opened cycle (19, Scheme 4). 
 
 
Figure 2. Design of the methyleneoxazol-5(4H)-one scaffold (II). 
 
Results and discussion 
 
Chemistry 
The synthetic pathways for obtaining the target benzylidene-oxazolone compounds 2, 3, 4, 16a-
c, 17a-c, 18a-c are outlined in Schemes 1, 2 and 3. Benzylidene-oxazolones were obtained in one 
step by Erlenmeyer-Plöchl condensation17-18 of the appropriately substituted aromatic aldehydes 
with N-acetylglycine and sodium acetate in refluxing acetic anhydride. This reaction furnished only 
the thermodynamically stable (Z)-isomers in most cases, with the exception of heteroaromatic 
oxazolones 3 and 4, which were obtained with a minimal percentage of the corresponding (E)-
isomer, as detected by 1H-NMR spectra (9% and 7% for 3 and 4, respectively)19. Unlike 
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commercially available benzaldehyde 5 (Scheme 1) and 2-furaldehyde 6 (Scheme 2), pyrrole-2-
carboxaldehyde 7 was subjected to the same condensation with N-acetylglycine but the desired 
oxazolone derivative 8 was not formed. In fact, under these conditions, only the heterocyclic 
nitrogen of 7 resulted as being acetylated, yielding compound 9. After isolation and identification of 
9, it was again submitted to the same procedure to obtain the acetyl-pyrrol-methyloxazol-5(4H)-one 
4 (Scheme 2). Attempts to obtain pyrrole derivative 8 from its acetylated analogue 4 were 
unsuccessful. 
 
 
Scheme 1. Reagents and conditions: a) N-acetylglycine, Ac2O, CH3COONa, reflux, 5h. 
 
 
Scheme 2. Reagents and conditions: a) N-acetylglycine, Ac2O, CH3COONa, reflux, 5h. 
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A series of phenyl-substituted analogues of compound 2 were prepared in order to investigate the 
effects caused by the variation of aromatic rings inserted in various positions on the phenyl of the 
promising compound 2 (see Biological evaluation section), in the light of the consideration that 
many of the known MAGL inhibitors simply consist of a lipophilic scaffold to which a heterocyclic 
system is bound. We therefore evaluated a series of slightly different lipophilic backbones linked to 
the same 2-methyloxazol-5(4H)-one moiety. Commercially available ortho-, meta- and para-
bromo-substituted benzaldehydes 10-12 were subjected to a Pd-catalyzed cross-coupling reaction 
under classical Suzuki conditions (Scheme 3)20. In particular, bromo-derivatives 10-12 were treated 
with the appropriate unsubstituted (R1 = H; Scheme 3) or para-substituted (R1 = fluoro, methoxy; 
Scheme 3) phenylboronic acids under conventional heating at 100 °C, producing the desired 
arylsubstituted aldehydes 13a-c, 14a-c and 15a-c in good yields (Scheme 3), which then followed 
the same condensation reaction seen before (Scheme 1) for the formation of the oxazolone cycle to 
obtain compounds 16a-c, 17a-c and 18a-c. 
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S
cheme 3. Reagents and conditions: a) appropriately substituted phenylboronic acid, Pd(OAc)2, 
PPh3, aq. 2M Na2CO3, toluene, EtOH, 100 °C, 24 h; b) N-acetylglycine, Ac2O, CH3COONa, reflux, 
5h. 
 
Moreover, in order to further support the hypothesized action mechanism of these MAGL 
inhibitors, the oxazolone ring of the representative compound 18a was opened to verify the key role 
played by the cyclic portion of these compounds in alkylating the enzyme’s catalytic serine by 
opening the lactone ring. Therefore, compound 18a was hydrolyzed under basic conditions, 
followed by acidification to obtain biphenylacetamidoacrylic acid derivative 1921, which was then 
submitted to biological assays as a valuable tool for establishing the pharmacophoric portion needed 
for MAGL inhibition (Scheme 4). 
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Scheme 4. Reagents and conditions: a) NaOH 1N, 90 °C, then HCl 3N, 0 °C. 
 
Biological evaluation. 
The inhibitory effects of the newly synthesized compounds on human isoforms of MAGL and 
FAAH (hMAGL and hFAAH) are reported in Table 1, together with those of two reference 
inhibitors (CAY10499 and JZL-184). Among the three smallest compounds 2-4, phenyl-substituted 
compound 2 displayed the most promising activity against MAGL (IC50 = 24.1 M) and an 
unexpectedly high selectivity against FAAH, showing no detectable activity on this enzyme. 
Differently, 3 and 4 were weak MAGL inhibitors and inactive on FAAH. Encouraged by these first 
results, the series of differently substituted (Z)-biphenyl derivatives 16a-c, 17a-c and 18a-c were 
tested. All the reported compounds showed IC50 values in the range of 1.0-2.2 µM on MAGL and a 
FAAH inhibitory activity in the range of 33.9-111 µM. The position of the distal phenyl and the 
para-substituent present on this ring did not seem to significantly influence the activity of the 
resulting compounds. Very interestingly, even if these compounds are not very potent inhibitors, 
they showed a very high selectivity ratio for MAGL versus FAAH, comparable to that observed for 
JZL-184, one of the most active and selective MAGL inhibitors currently available (see Table 1)10. 
In particular, among the ortho-biphenyl derivatives, the para-fluoro compound 16b was the most 
selective inhibitor (69-fold, IC50 MAGL = 1.6 M, IC50 FAAH = 111 M). In order to verify the 
importance of the 2-methyl-4-methyleneoxazol-5(4H)-one ring for the interaction of these 
compounds with enzyme, compound 19, the analogue of 18a with the oxazolone ring open, was 
tested under the same conditions. This acetamidoacetic acid derivative showed a substantial loss of 
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MAGL inhibitory activity, thus supporting the importance of the oxazolone ring for interaction with 
the enzyme.  
 
Table 1. Experimental inhibition activity (IC50) on human MAGL and FAAH of the analyzed 
compounds. 
# 
MAGL IC50 
(µM) 
FAAH IC50 
(µM) 
Selectivity 
2 24.1 ± 0.2 > 200 > 20 
3 116 ± 7 > 200 > 2 
4 > 200 > 200 / 
16a 2.1 ± 0.3 94.0  ± 3.7 45 
16b 1.6 ± 0.2 111 ± 7 69 
16c 2.2 ± 0.2 33.9 ± 0.0 15 
17a 1.2 ± 0.1 52.3 ± 3.6 44 
17b 1.1 ± 0.1 69.1 ± 5.3 63 
17c 1.0 ± 0.1 48.9 ± 0.8 49 
18a 1.1 ± 0.1 45.4 ± 2.0 41 
18b 1.7 ± 0.1 67.3 ± 2.8 40 
18c 1.3 ± 0.1 37.3 ± 6.8 29 
19 > 200 > 200 / 
CAY10499 0.144 ± 0.003 0.014 ± 0.001 0.1 
JZL-184 0.049 ± 0.004  3.3 ± 0.2 67 
 
Furthermore, in order to verify if the compounds could interact with cysteines of the MAGL 
enzyme, the activity of the most selective compound 16b was also tested in the presence of the 
thiol-containing agent 1,4-dithio-DL-threitol (DTT)22. As shown in Figure 3A, the hMAGL-IC50 
value of compound 16b was only very slightly influenced by the presence of DTT, shifting from 1.7 
M in the absence of DTT to 2.0 M when assayed with 10 M DTT, thus excluding the interaction 
of these compounds with the cysteine residues of the MAGL enzyme. In order to study the 
inhibition mechanism of the new reported compounds, the effects of dilution and preincubation on 
the inhibitory ability of compound 16b were evaluated. In the dilution experiments, if 16b is an 
irreversible inhibitor, then its inhibition potency should not drop upon dilution, whereas inhibition 
levels should be substantially reduced upon dilution in the presence of a reversible compound. As 
shown in Figure 3B, 16b showed reversible inhibition, since the inhibition produced by 40 µM of 
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the compound was significantly higher compared with the inhibition observed with a 40X dilution, 
which appears similar to that produced by a 1 µM concentration of the compound. In order to 
further support these results, the activity of 16b was tested at different preincubation times of the 
inhibitor with the enzyme. In principle, an irreversible inhibitor will increase its capacity to block 
the enzyme with increasingly longer incubation times in the presence of the enzyme prior to 
addition of the substrate; a constant IC50 value, conversely, supports a reversible mechanism
23. As 
expected, compound 16b did not show any significant increase in its ability to block MAGL activity 
after 30 and 60 minutes (Figure 3C), suggesting that its binding to MAGL is reversible. 
 
 
Figure 3. Compound 16b-hMAGL inhibition analysis. A) Effect of DTT on the hMAGL inhibition 
properties. B) Dilution assay: the first two columns indicate the inhibition percentage of compound 
16b at a concentration of 40 µM and 1 µM. The third column indicates the inhibition percentage of 
compound 16b after dilution (final concentration = 1 µM). C) IC50 (µM) values of 16b at different 
preincubation times with hMAGL (0 min, 30 min and 60 min). 
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Compounds 16b, 17b and 18b were also selected for in vitro experiments to evaluate their 
antiproliferative potency on selected cancer cells. Four tumor cell lines were chosen: the human 
breast MDA-MB-231 and MCF-7, and the human ovarian cancer cells COV318 and OVCAR-3. 
These cell lines were selected because of the critical role of MAGL in the tumor progression of 
breast and ovarian cancers23-24. All three compounds produced appreciable inhibition of cell 
viability, with IC50 values ranging from 10.0 to 54.4 µM (see Table 2). When compared to the 
covalent reference inhibitors JZL-184 and CAY10499, compounds 16b-18b showed similar 
activity profiles, and compound 16b demonstrated an even better overall cytotoxicity on the ovarian 
cell lines, thus supporting the hypothesis that a reversible MAGL inhibition mechanism could be 
considered as an interesting approach for studying the MAGL inhibition effects on cancer cell 
proliferation. 
 
Table 2. Cell growth inhibitory activities (IC50) of compounds 
 IC50 (µM) 
# MCF-7 MB-231 COV318 OVCAR-3 
16b 18.1 ± 2.8 42.1 ± 4.2 42.1 ± 5.1 10.0 ± 1.9 
17b 15.8 ± 2.3 38.1 ± 4.2 50.5 ± 6.1 28.8 ± 3.5 
18b 23.7 ± 1.8 54.4 ± 4.8 50.2 ± 5.1 18.0 ± 3.2 
JZL-184 26.0 ± 5.1 37.8 ± 5.0 56.6 ± 3.2 52.9 ± 5.7 
CAY10499a 4.2 ± 1.2 46.0 ± 6.9 106.7 ± 21.5 79.8 ± 11.7 
a Ref 23 
 
Docking studies. 
The three most promising ligands (16b, 17b and 18b) and CAY10499 were docked into human 
MAGL and humanized-rat FAAH using GOLD 5.125. This docking analysis can help to analyze the 
interaction of the compounds before the formation of the covalent bond with the catalytic serine, 
thus highlighting the most important interactions for ligand recognition. In human MAGL, the 2-
methyloxazolone rings of all three new compounds were placed near the catalytic S122, with the 
formation of one H-bond with the hydroxyl group of the serine and a second H-bond with the 
13 
 
nitrogen backbone of A51 (see Figure 4). For all three ligands, the benzylidene fragment acted as a 
linker, without showing important interactions, but allowing the interaction of the p-fluorophenyl 
ring into a lipophilic pocket mainly delimited by M88, L176, G177, P178, I179 and L205. The 
oxadiazolone ring of the reference compound CAY10499 showed a very similar disposition to that 
of the 2-methyloxazolone ring of 16b, 17b and 18b, with the two H-bonds with the hydroxyl group 
of S122 and the nitrogen backbone of A51. Similarly to 16b, 17b and 18b, the 3-methylphenyl 
central portion of the molecule did not show important interactions with the protein, but allowed the 
proper localization of the benzylcarbamate portion in a lipophilic pocket mainly delimited by L148, 
A151, L213, L214, and V217 (see Figure 4D).  
 
 
Figure 4. Docking of 16b (A), 17b (B), 18b (C), and CAY10499 (D) into the human MAGL 
receptor. 
 
Figure 5A shows the docking of compound CAY10499 into humanized-rat FAAH. Similarly to 
what was observed with the MAGL binding site and in considerable agreement with its good 
inhibitory activity on both enzymes, the oxadiazolone ring of this compound was placed near the 
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catalytic S241 with the formation of one H-bond with the hydroxyl group of the serine and a second 
H-bond with the nitrogen backbone of I238. The 3-methylphenyl central portion of the molecule 
showed lipophilic interactions with F192 and F244, whereas the benzylcarbamate fragment showed 
lipophilic interactions with Y194, L401 and L404. Conversely, the binding site shape of FAAH does 
not seem to allow the interaction of the 2-methyloxazolone ring of compounds 16b, 17b and 18b in 
proximity to the catalytic region of the enzyme (Figure 5), since all three compounds showed 
binding dispositions that are completely different from that observed in the MAGL binding site, and 
none of them allowed the interaction of the 2-methyloxazolone ring with the catalytic S241. The 
rigid geometry imposed by the (Z)-4-benzylidene-2-methyloxazol-5(4H)-one portion, which could 
not fit into the catalytic region of the FAAH enzyme, is probably the cause of the low activity 
shown by these compounds for FAAH and, therefore, the great selectivity for MAGL. 
 
 
Figure 5. Docking of CAY10499 (A), 16b (B), 17b (C), and 18b (D) into humanized-rat FAAH 
receptor. 
 
Conclusions. 
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Chanda and co-workers reported that the genetic MAGL inactivation in mouse models 
determined a dramatic reduction of the 2-AG hydrolase activity with the consequent presence of 
elevated 2-AG levels in the nervous system26. Furthermore, differently from FAAH, the chronic 
pharmacological blockade of MAGL determined receptor desensitization and pharmacological 
tolerance with cross-tolerance to CB1 cannabinoid receptor agonists, impaired endocannabinoid-
dependent synaptic plasticity and CB1 brain receptor desensitization
27. Taken together, these results 
could discourage the development of new MAGL inhibitors, however the use of low-doses of JZL-
184 induced anxiolytic-like effects that were also maintained after chronic treatment28. Chen et al., 
by using an intermittent dosage regimen, obtained a significantly diminished amyloid 
neuropathology, reduced neuroinflammation and degeneration, and improved synaptic and 
cognitive function in animal model of Alzheimer's disease29. These two latter studies support the 
hypothesis that irreversible inhibition of MAGL should be avoided. Beyond the possibility of using 
a low or intermittent dosage regimen, a third way which has not yet been explored is the application 
of selective reversible MAGL inhibitors. In the present work we report a new class of MAGL 
inhibitors characterized by high selectivity, reversible properties and good activity in 
antiproliferative assays. Molecular modeling and SAR studies support the hypothesis that the key 
fragment for selectivity is the 2-methyloxazol-5(4H)-one scaffold. Further computational and 
synthetic efforts will be carried out in order to improve the activity and selectivity of the herein 
reported chemical class of MAGL inhibitors, in order to candidate them as new leads for in vivo 
inhibition of the MAGL enzyme. 
 
Experimental protocols 
 
Chemistry 
General  
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Commercially available chemicals were purchased from Sigma-Aldrich or Alfa Aesar and used 
without further purification. PS-TsNHNH2 was purchased from Argonaut Technologies Inc and 
JZL-184 and CAY10499 were purchased from Cayman Chemical. NMR spectra were obtained 
with a Bruker Avance III 400 MHz spectrometer. Chemical shifts () are reported in parts per 
million downfield from tetramethylsilane and referenced from solvent references. Chromatographic 
separations were performed on silica gel columns by flash chromatography (Kieselgel 60, 0.040–
0.063 mm; Merck). Reactions were followed by thin-layer chromatography (TLC) on Aldrich 
aluminum silica gel (F254) sheets that were visualized under a UV lamp. Evaporation was 
performed in vacuo (rotating evaporator). Sodium sulfate was always used as the drying agent. 
 
General procedure for the preparation of the oxazole derivatives 2, 3, 4, 16a-c, 17a-c, 18a-c. 
A mixture of properly substituted aromatic aldehydes 5, 6, 9, 13a-c, 14a-c or 15a-c (1 eq), N-
acetylglycine (1 eq) and sodium acetate (1 eq) in acetic anhydride (5 mL/5 mmol aldehyde) was 
stirred at reflux for 5 h and then warmed slowly to room temperature over 16 h. The reaction was 
quenched with water and extracted with AcOEt. The organic layer was washed sequentially with 
water and saturated brine, dried over Na2SO4 and the solvent was removed under reduced pressure. 
The residue was purified with a flash column chromatography using the indicated eluent and pure 
fractions containing the desired compound were evaporated to dryness affording the desired 
product. 
 
(Z)-4-Benzylidene-2-methyloxazol-5(4H)-one (2). 
yellow crystalline solid, yield: 47% (417.1 mg) from 5. Rf = 0.14 (n-hexane/EtOAc 95:5).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.41 (s, 3H), 7.15 (s, 1H), 7.42-7.47 (m, 3H), 8.07-8.09 (m, 
2H). 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.84, 129.03 (3C), 131.28, 131.65, 132.31, 132.70, 133.27, 
166.26, 167.97. 
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(Z)-4-(Furan-2-ylmethylene)-2-methyloxazol-5(4H)-one (3). 
bright yellow crystalline solid, yield: 49% (451.2 mg) from 6. Rf = 0.18 (n-hexane/EtOAc 9:1).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.40 (s, 3H), 6.59 (dd, 1H, J = 3.6, 1.8 Hz), 7.03 (s, 1H), 7.28 
(d, 1H, J = 3.6 Hz), 7.68 (d, 1H, J = 1.3 Hz). Signals attributed to the (E) isomer (9%): 2.34 (s, 3H), 
6.62-6.63 (m, 1H), 7.63 (d, 1H, J = 1.5 Hz), 8.03 (d,1H, J = 3.6 Hz). 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.82, 113.57, 118.00, 120.17, 129.57, 147.06, 150.08, 
165.88, 167.54. 
 
(Z)-4-((1-Acetyl-1H-pyrrol-2-yl)methylene)-2-methyloxazol-5(4H)-one (4). 
bright yellow crystalline solid, yield: 18% (68.0 mg) from 9. Rf = 0.12 (n-hexane/Et2O 6:4).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.37 (s, 3H), 2.62 (s, 3H), 6.43 (t, 1H, J = 3.3 Hz), 7.30 (dd, 
1H, J = 3.3, 1.4 Hz), 7.69-7.71 (m, 1H), 8.18 (s, 1H). Signals attributed to the (E) isomer (7%): 2.32 
(s, 3H), 2.63 (s, 3H), 7.33 (dd, 1H, J = 3.3, 1.2 Hz), 8.40 (s, 1H). 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.79, 24.59, 114.13, 121.45, 124.54, 125.62, 130.38, 
130.60, 165.25, 167.62, 169.53. 
 
1-Acetyl-1H-pyrrole-2-carbaldehyde (9). 
brown-orange solid, yield: 33% (94.0 mg) from 7. Rf = 0.12 (n-hexane/ EtOAc 8:2).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.66 (s, 3H), 6.36 (t, 1H, J = 3.3 Hz), 7.21 (dd, 1H, J = 3.6, 
1.6 Hz), 7.33 (dd, 1H, J = 3.1, 1.6 Hz), 10.29 (s, 1H). 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 24.12, 112.97, 122.98, 126.75, 135.76, 169.24, 182.58. 
 
(Z)-4-([1,1'-Biphenyl]-2-ylmethylene)-2-methyloxazol-5(4H)-one (16a). 
yellow crystalline solid, yield: 16% (107.0 mg) from 13a. Rf = 0.13 (n-hexane/EtOAc 9:1).
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1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.42 (s, 3H), 7.21 (s, 1H), 7.30-7.33 (m, 2H), 7.38- 7.50 (m, 
6H), 8.65-8.69 (m, 1H). 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.84, 127.83, 128.04, 128.58 (2C), 130.06 (2C), 130.51, 
130.53, 130.80, 130.96, 132.11, 132.80, 139.89, 145.08, 166.33, 167.70. 
 
(Z)-4-((4'-Fluoro-[1,1'-biphenyl]-2-yl)methylene)-2-methyloxazol-5(4H)-one (16b). 
bright yellow crystalline solid, yield: 24% (137.0 mg) from 13b. Rf = 0.14 (n-hexane/EtOAc 95:5).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.42 (s, 3H), 7.10-7.17 (m, 3H), 7.26-7.30 (m, 2H), 7.35-7.38 
(m, 1H), 7.45-7.48 (m, 2H), 8.64-8.66 (m, 1H). 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.88, 115.67 (d, 2C, J = 21.1 Hz), 128.03, 130.04, 130.53, 
130.87, 131.05, 131.68 (d, 2C, J = 8.0 Hz), 132.18, 133.02, 135.91 (d, J = 3.0 Hz), 143.93, 162.79 
(d, J = 247.5 Hz), 166.57, 167.67. 
 
(Z)-4-((4'-Methoxy-[1,1'-biphenyl]-2-yl)methylene)-2-methyloxazol-5(4H)-one (16c). 
bright yellow crystalline solid, yield: 15% (83.3 mg) from 13c. Rf = 0.18 (n-hexane/EtOAc 9:1).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.42 (s, 3H), 3.87 (s, 3H), 6.98 (AA’XX’, 2H, JAX = 8.7 Hz, 
JAA’/XX’ = 2.5 Hz), 7.22-7.25 (m, 3H), 7.37-7.42 (m, 1H), 7.44-7.48 (m, 2H), 8.62-8.64 (m, 1H).
 
13C-NMR (CDCl3, 100 MHz) δ (ppm):15.85, 55.50, 114.11 (2C), 127.48, 130.52, 130.83, 130.87, 
131.01, 131.26 (2C), 132.13, 132.24, 132.64, 144.83, 159.62, 166.18, 167.81. 
 
(Z)-4-([1,1'-Biphenyl]-3-ylmethylene)-2-methyloxazol-5(4H)-one (17a). 
bright yellow crystalline solid, yield: 43% (530.0 mg) from 14a. Rf = 0.15 (n-hexane/EtOAc 95:5).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.42 (s, 3H), 7.21 (s, 1H), 7.39 (tt, 1H, J = 7.3, 1.5 Hz), 7.45-
7.50 (m, 2H), 7.52 (t, 1H, J = 7.8 Hz), 7.61-7.67 (m, 3H), 8.08-8.11 (m, 1H), 8.28 (t, 1H, J = 1.7 
Hz). 
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13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.86, 127.33 (2C), 127.85, 129.04 (3C), 129.46, 130.03, 
131.03, 131.48, 133.02, 133.77, 140.47, 142.05, 166.37, 167.95. 
 
(Z)-4-((4'-Fluoro-[1,1'-biphenyl]-3-yl)methylene)-2-methyloxazol-5(4H)-one (17b). 
white crystalline solid, yield: 45% (382.0 mg) from 14b. Rf = 0.11 (n-hexane/EtOAc 95:5).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.42 (s, 3H), 7.16 (double AA’XX’, 2H, 
3JHF-o = 9.8 Hz, JAX 
= 8.7 Hz, JAA’/XX’ = 2.6 Hz), 7.20 (s, 1H), 7.51 (t, 1H, J = 7.7 Hz), 7.55-7.62 (m, 3H), 8.05-8.09 (m, 
1H), 8.25 (t, 1H, J = 1.7 Hz). 
13C-NMR (Acetone-d6, 100 MHz) δ (ppm): 15.67, 116.47, 116.69, 129.78 (d, 2C, J = 9.1 Hz), 
130.13, 130.41 (d, 2C, J = 21.1 Hz), 131.45, 131.72, 134.37, 135.05, 137.48 (d, J = 2.0 Hz), 141.39, 
163.61 (d, J = 244.5 Hz), 168.02, 168.19. 
 
(Z)-4-((4'-Methoxy-[1,1'-biphenyl]-3-yl)methylene)-2-methyloxazol-5(4H)-one (17c). 
After an initial purification, compound 17c was obtained as a mixture with starting material 14c, 
therefore this mixture dissolved in dry THF was stirred in the presence of polystyrene sulfonyl 
hydrazide (PS-TsNHNH2, 3 eq relative to aldehyde, minimum capacity 2.2 mmol/g) until 
disappearance of the starting material. Then the reaction was filtered and washed with THF and the 
filtrate was evaporated and concentrated under vacuum, to afford a crude residue that was purified 
by column chromatography.  
bright yellow crystalline solid, yield: 17% (94.7 mg) from 14c. Rf = 0.21 (n-hexane/EtOAc 9:1).
 
1H-NMR (Acetone-d6, 400 MHz) δ (ppm): 2.42 (s, 3H), 3.86 (s, 3H), 7.06 (AA'XX', 2H, JAX = 8.8 
Hz, JAA'/XX' = 2.6 Hz), 7.21 (s, 1H), 7.55 (t, 1H, J = 7.8 Hz), 7.66 (AA'XX', 2H, JAX = 8.8 Hz, JAA'/XX' 
= 2.6 Hz), 7.72 (dt, 1H, J = 7.8, 1.4 Hz), 8.18-8.20 (m, 1H), 8.43 (t, 1H, J = 1.7 Hz). 
13C-NMR (Acetone-d6, 100 MHz) δ (ppm): 15.65, 55.66, 115.27, 128.87 (3C), 129.78, 130.16, 
130.82, 131.07 (2C), 133.34, 134.17, 134.93, 142.11, 160.69, 167.83, 168.24. 
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(Z)-4-([1,1'-Biphenyl]-4-ylmethylene)-2-methyloxazol-5(4H)-one (18a). 
bright yellow crystalline solid, yield: 47% (336.0 mg) from 15a. Rf = 0.13 (n-hexane/EtOAc 95:5).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.43 (s, 3H), 7.19 (s, 1H), 7.37-7.42 (m, 1H), 7.45-7.49 (m, 
2H), 7.63-7.65 (m, 2H), 7.68-7.70 (m, 2H), 8.15-8.17 (m, 2H). 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.88, 127.30 (2C), 127.65 (2C), 128.26, 129.11 (2C), 
131.21, 132.31, 132.61, 132.83 (2C), 140.17, 143.88, 166.17, 168.00. 
 
(Z)-4-((4'-Fluoro-[1,1'-biphenyl]-4-yl)methylene)-2-methyloxazol-5(4H)-one (18b). 
bright yellow crystalline solid, yield: 22% (154.0 mg) from 15b. Rf = 0.18 (n-hexane/EtOAc 9:1).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.43 (s, 3H), 7.14-7.19 (m, 3H), 7.60 (double AA’XX’, 2H, 
4JHF-m = 5.3 Hz, JAX = 8.8 Hz, JAA’/XX’ = 2.5 Hz), 7.61-7.65 (m, 2H), 8.13-8.17 (m, 2H).
 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.86, 116.01 (d, 2C, J = 21.1 Hz), 127.46 (2C), 128.93 (d, 
2C, J = 8.0 Hz), 130.98, 132.33, 132.72, 132.86 (2C), 136.30 (d, J = 4.0 Hz), 142.79, 163.08 (d, J = 
247.5 Hz), 166.26, 167.92.  
 
(Z)-4-((4'-Methoxy-[1,1'-biphenyl]-4-yl)methylene)-2-methyloxazol-5(4H)-one (18c). 
bright yellow crystalline solid, yield: 23% (159.4 mg) from 15c. Rf = 0.14 (n-hexane/EtOAc 9:1).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 2.42 (s, 3H), 3.87 (s, 3H), 7.00 (AA’XX’, 2H, JAX = 8.8 Hz, 
JAA’/XX’ = 2.6 Hz), 7.18 (s, 1H), 7.59 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.6 Hz), 7.64 (AA’XX’, 
2H, JAX = 8.5 Hz, JAA’/XX’ = 1.8 Hz), 8.11-8.15 (m, 2H).
 
13C-NMR (CDCl3, 100 MHz) δ (ppm): 15.84, 55.53, 114.57 (2C), 127.04 (2C), 128.37 (2C), 
131.33, 131.69, 132.28, 132.55, 132.86 (2C), 143.48, 160.00, 165.92, 168.04. 
 
General procedure for the formation of biphenyl derivatives 13a-c, 14a-c and 15a-c.  
A solution of Pd(OAc)2 (0.03 eq) and triphenylphosphine (0.15 eq) in ethanol (6 mL/2.7 mmol 
bromo-derivative) and toluene (6 mL/2.7 mmol bromo-derivative) was stirred at RT under nitrogen 
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for 10 min. After that period, commercially available bromo-substituted aldehydes 10-12 (1 eq), 2M 
aqueous Na2CO3 (6 mL/2.7 mmol bromo-derivative), and the appropriate substituted phenylboronic 
acid (1.6 eq) were sequentially added. The resulting mixture was heated at 100 °C in a sealed vial 
under nitrogen for 24 h. After being cooled to RT, the mixture was diluted with water and extracted 
with EtOAc. The combined organic phase were dried and concentrated. The crude product was 
purified by flash chromatography using the indicated eluent and pure fractions containing the 
desired biphenyl compound were evaporated to dryness affording the desired product. 
 
[1,1'-Biphenyl]-2-carbaldehyde (13a). 
yellow oil, yield: 76% (490.3 mg) from aldehyde 10 and phenylboronic acid. Rf = 0.16 (n-
hexane/EtOAc 98:2). 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 7.38-7.40 (m, 2H), 7.44-7.53 (m, 5H), 7.65 (td, 1H, J = 7.5, 
1.5 Hz), 8.04 (ddd, 1H, J = 7.8, 1.4, 0.4 Hz), 9.99 (s, 1H). 
 
4'-Fluoro-[1,1'-biphenyl]-2-carbaldehyde (13b). 
white solid, yield: 99% (619.3 mg) from aldehyde 10 and 4-fluorophenylboronic acid. Rf = 0.20 (n-
hexane/EtOAc 95:5). 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 7.17 (double AA’XX’, 2H, 
3JHF-o = 9.5 Hz, JAX = 8.6 Hz, 
JAA’/XX’ = 2.5 Hz), 7.36 (double AA’XX’, 2H, 
4JHF-m = 5.3 Hz, JAX = 8.6 Hz, JAA’/XX’ = 2.5 Hz), 7.42 
(dd, 1H, J = 7.7, 0.7 Hz), 7.48-7.53 (m, 1H), 7.64 (td, 1H, J = 7.5, 1.4 Hz), 8.02 (dd, 1H, J = 7.8, 
1.3 Hz), 9.97 (s, 1H). 
 
4'-Methoxy-[1,1'-biphenyl]-2-carbaldehyde (13c). 
light yellow oil, yield: 99% (667.7 mg) from aldehyde 10 and 4-methoxyphenylboronic acid. Rf = 
0.14 (n-hexane/EtOAc 95:5). 
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1H-NMR (CDCl3, 400 MHz) δ (ppm): 3.88 (s, 3H), 7.01 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.5 
Hz), 7.31 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.5 Hz), 7.42-7.49 (m, 2H), 7.62 (td, 1H, J = 7.5, 
1.4 Hz), 8.00 (dd, 1H, J = 7.8, 1.4 Hz), 10.00 (s, 1H). 
 
[1,1'-Biphenyl]-3-carbaldehyde (14a). 
light yellow oil, yield: 88% (868.0 mg) from aldehyde 11 and phenylboronic acid. Rf = 0.28 (n-
hexane/EtOAc 95:5). 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 7.40 (tt, 1H, J = 7.3, 1.6 Hz), 7.46-7.51 (m, 2H), 7.59-7.65 
(m, 3H), 7.85-7.89 (m, 2H), 8.11 (t, 1H, J = 1.5 Hz), 10.10 (s, 1H). 
 
4'-Fluoro-[1,1'-biphenyl]-3-carbaldehyde (14b). 
colorless oil, yield: 99% (668.9 mg) from aldehyde 11 and 4-fluorophenylboronic acid. Rf = 0.14 (n-
hexane/EtOAc 95:5). 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 7.17 (double AA’XX’, 2H, 
3JHF-o = 9.8, Hz, JAX = 8.7 Hz, 
JAA’/XX’ = 2.6 Hz), 7.56-7.63 (m, 3H), 7.81 (ddd, 1H, J = 7.8, 1.9, 1.2 Hz), 7.86 (dt, 1H, J = 7.6, 1.4 
Hz), 8.05 (t, 1H, J = 1.6 Hz), 10.09 (s, 1H). 
 
4'-Methoxy-[1,1'-biphenyl]-3-carbaldehyde (14c). 
white crystalline solid, yield: 99% (791.0 mg) from aldehyde 11 and 4-methoxyphenylboronic acid. 
Rf = 0.12 (n-hexane/EtOAc 95:5).
 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 3.87 (s, 3H), 7.01 (AA'XX', 2H, JAX = 8.9 Hz, JAA'/XX'= 2.6 
Hz), 7.55-7.60 (m, 3H), 7.80-7.84 (m, 2H), 8.06 (t, 1H, J = 1.6 Hz), 10.08 (s, 1H). 
 
[1,1'-Biphenyl]-4-carbaldehyde (15a). 
light yellow solid, yield: 92% (909.8 mg) from aldehyde 12 and phenylboronic acid. Rf = 0.23 (n-
hexane/EtOAc 95:5). 
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1H-NMR (CDCl3, 400 MHz) δ (ppm): 7.42 (td, 1H, J = 7.3, 1.7 Hz), 7.46-7.52 (m, 2H), 7.63-7.66 
(m, 2H), 7.76 (AA'XX', 2H, JAX = 8.4 Hz, JAA'/XX'= 2.1 Hz), 7.96 (AA'XX', 2H, JAX = 8.4 Hz, 
JAA'/XX'= 1.7 Hz), 10.06 (s, 1H). 
 
4'-Fluoro-[1,1'-biphenyl]-4-carbaldehyde (15b). 
white solid, yield: 98% (527.2 mg) from aldehyde 12 and 4-fluorophenylboronic acid. Rf = 0.17 (n-
hexane/EtOAc 95:5). 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 7.17 (double AA’XX’, 2H, 
3JHF-o = 9.7, Hz, JAX = 8.7 Hz, 
JAA’/XX’ = 2.6 Hz), 7.61 (double AA’XX’, 2H, 
4JHF-m = 5.3, Hz, JAX = 8.9 Hz, JAA’/XX’ = 2.6 Hz), 7.70 
(AA’XX’, 2H, JAX = 8.2 Hz, JAA’/XX’= 1.7 Hz), 7.95 (AA’XX’, 2H, JAX = 8.5 Hz, JAA’/XX’= 1.8 Hz), 
10.06 (s, 1H).  
 
4'-Methoxy-[1,1'-biphenyl]-4-carbaldehyde (15c). 
white solid, yield: 95% (542.0 mg) from aldehyde 12 and 4-methoxyphenylboronic acid. Rf = 0.18 
(n-hexane/EtOAc 95:5). 
1H-NMR (CDCl3, 400 MHz) δ (ppm): 3.87 (s, 3H), 7.01 (AA’XX’, 2H, JAX = 8.9 Hz, JAA’/XX’= 2.6 
Hz), 7.60 (AA’XX’, 2H, JAX = 8.9 Hz, JAA’/XX’= 2.6 Hz), 7.72 (AA’XX’, 2H, JAX = 8.2 Hz, JAA’/XX’= 
1.7 Hz), 7.93 (AA’XX’, 2H, JAX = 8.5 Hz, JAA’/XX’= 1.8 Hz), 10.04 (s, 1H). 
 
Procedure for synthesis of compound (Z)-3-([1,1'-biphenyl]-4-yl)-2-acetamidoacrylic acid (19). 
A suspension of azlactone 18a (150 mg, 0.570 mmol) in 1.5 mL of 1 N sodium hydroxide solution 
was heated at 90 °C until homogeneous. The clear solution was cooled in an ice bath and then was 
acidified to pH 1-2 with a hydrochloric acid solution 3 N and a white precipitate was formed. The 
precipitate thus formed was isolated by filtration and washed with distilled water. The precipitate 
was then dissolved in acetone, dried, filtered and evaporated under reduced pressure to obtain a 
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white solid. The solid was further purified by crystallization in n-hexane/EtOAc to afford the pure 
desired compound 19 in 14% yield (21.8 mg) as white crystals. 
1H-NMR (DMSO-d6, 400 MHz) δ (ppm): 2.01 (s, 3H), 7.26 (s, 1H), 7.36-7.41 (m, 1H), 7.46-7.50 
(m, 2H), 7.69-7.74 (m, 6H), 9.53 (bs, 1H), 12.66 (bs, 1H). 
13C-NMR (DMSO-d6, 100 MHz) δ (ppm): 22.56, 126.61 (2C), 126.66 (2C), 127.36, 127.82, 129.01 
(3C), 130.35, 130.50, 132.88, 139.26, 140.53, 166.37, 169.13. 
 
Biological evaluation  
 
MAGL inhibition assay 
Human recombinant MAGL, and 4-nitrophenylacetate substrate (4-NPA) were from Cayman 
Chemical. The IC50 values for compounds were generated in 96-well microtiter plates. The MAGL 
reaction was conducted at room temperature at a final volume of 200 µL in 10 mM Tris buffer, pH 
7.2, containing 1 mM EDTA. A total of 150 µL of 4-NPA 133.3 µM (final concentration = 100 μM) 
was added to 10 µL of DMSO containing the appropriate amount of compound. The reaction was 
initiated by the addition of 40 µL of MAGL (11 ng/well) in such a way that the assay was linear 
over 30 min. The final concentration of the analyzed compounds ranged for CAY10499 and JZL-
184 from 10 to 0.00001 µM and for the synthesized compounds from 200 to 0.0128 µM. After the 
reaction had proceeded for 30 min, absorbance values were then measured by using a VictorX3 
PerkinElmer instrument at 405 nm. Two reactions were also run: one reaction containing no 
compounds and the second one containing neither inhibitor nor enzyme. IC50 values were derived 
from experimental data using the Sigmoidal dose–response fitting of GraphPad Prism software. To 
remove possible false positive results, for each compound concentration a blank analysis was 
carried out, and the final absorbance results were obtained detracting the absorbance produced by 
the presence of all the components except MAGL in the same conditions. 
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DTT interference assay 
The inhibition assay was the same described above, with the exception that prior to the addition of 
40 µL of MAGL (11 ng/well), the compound-substrate mixture was incubated 15 min in the 
presence of DTT at a 10 µM concentration. 
 
MAGL preincubation assay 
The MAGL reaction was conducted at room temperature at a final volume of 200 µL in 10 mM Tris 
buffer, pH 7.2, containing 1 mM EDTA. A total of 150 µL of MAGL (11 ng/well) was added to 10 
µL of DMSO containing the appropriate amount of compound. After 0 min, 30 min, and 60 min of 
incubation time the reaction was initiated by the addition of 40 µL of 4-NPA 500 µM. The enzyme 
activity was then measured according to the procedure described above. 
 
MAGL dilution assay 
The enzyme (880 ng in 75 µL of Tris buffer, pH 7.2) was incubated during 60 min at room 
temperature with 5 µL of compound 16b (concentration of 40 µM in the mixture) dissolved in 
DMSO. The MAGL-inhibitor mixture was then diluted 40-fold with the buffer. After 15 min of 
incubation, the reaction was initiated on a 160 µL aliquot by the addition of 40 µL of 4-NPA 500 
µM and the enzyme activity was measured according to the procedure described above. 
 
FAAH inhibition assay 
The IC50 values for compounds were generated in 96-well microtiter plates. The FAAH reaction 
was conducted at room temperature at a final volume of 200 μL in 125 mM Tris buffer, pH 9.0, 
containing 1 mM EDTA. A total of 150 μL of AMC arachidonoylamide 13.3 μM (final 
concentration = 10 μM) was added to 10 μL of DMSO containing the appropriate amount of 
compound. The reaction was initiated by the addition of 40 μL of FAAH (0.9 µg/well) in such a 
way that the assay was linear over 30 min. The final concentration of the analyzed compounds 
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ranged for CAY10499 from 10 to 0.00001 µM and for the other compounds from 200 to 0.0128 
µM. After the reaction had proceeded for 30 min, fluorescence values were then measured by using 
a VictorX3 PerkinElmer instrument at an excitation wavelength of 340 nm and an emission of 460 
nm. Two reactions were also run: one reaction containing no compounds and the second one 
containing neither inhibitor nor enzyme. IC50 values were derived from experimental data using the 
Sigmoidal dose−response fitting of GraphPad Prism software. To remove possible false positive 
results, for each compound concentration a blank analysis was carried out, and the final 
fluorescence results were obtained detracting the fluorescence produced by the presence of all the 
components except FAAH in the same conditions. 
 
Cell viability assay 
MDA-MB-231, MCF-7, COV318, and OVCAR-3 (from ATCC) were maintained at 37 °C in a 
humidified atmosphere containing 5% CO2 accordingly to the supplier. Normal (1.5 × 10
4) and 
tumor (5 × 102) cells were plated in 96-well culture plates. The day after seeding, vehicle or 
compounds were added at different concentrations to the medium. Compounds were added to the 
cell culture at a concentration ranging from 200 to 0.02 µM. Cell viability was measured after 96 h 
according to the supplier (Promega, G7571) with a Tecan F200 instrument. IC50 values were 
calculated from logistical dose response curves. Averages were obtained from three independent 
experiments, and error bars are standard deviations (n = 3). 
 
Docking Studies 
The ligands were built by means of Maestro30 and were then minimized in a water environment 
(using the generalized Born/surface area model) by means of Macromodel31. They were minimized 
using the conjugate gradient, the MMFFs force field, and a distance-dependent dielectric constant 
of 1.0 until they reached a convergence value of 0.05 kcal Å−1 mol−1. The ligands were docked 
using GOLD 5.125 in the human MAGL (3JWE32 PDB code) and the humanized-rat FAAH (3LJ733 
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PDB code). The region of interest used by the docking software was defined in such a manner that 
it contained all the residues that stayed within 15 Å from the ligand in the X-ray structures; the 
possibility for the ligand to flip ring corners was activated, while the ‘allow early termination’ 
command was deactivated. For all the other parameters, the GOLD default ones were used, and the 
ligands were submitted to 30 genetic algorithm runs. The ChemPLP fitness scoring function was 
used. For each ligand, the best scored pose was taken into consideration. 
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